We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.51B
AUM Growth
-$254M
Cap. Flow
-$15.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
28.7%
Holding
145
New
11
Increased
46
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$25.7M
2
AMGN icon
Amgen
AMGN
+$24.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$19.6M
4
QURE icon
uniQure
QURE
+$11.2M
5
CNC icon
Centene
CNC
+$11.2M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$77.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$47.6M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$31.8M
4
PRAH
PRA Health Sciences, Inc.
PRAH
+$23.8M
5
A icon
Agilent Technologies
A
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 86.82%
2 Consumer Staples 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
51
Zai Lab
ZLAB
$2.62B
$18.6M 0.74%
575,000
+25,000
+5% +$858K
CELG
52
DELISTED
Celgene Corp
CELG
$18.4M 0.73%
185,150
– –
COLL icon
53
Collegium Pharmaceutical
COLL
$956M
$18.1M 0.72%
1,577,893
– –
FRPT icon
54
Freshpet
FRPT
$3.22B
$17.7M 0.7%
355,250
+120,250
+51% +$5.49M
ADPT icon
55
Adaptive Biotechnologies
ADPT
$3.97B
$16.8M 0.67%
545,000
-55,000
-9% -$2.24M
INSM icon
56
Insmed
INSM
$28.6B
$15.7M 0.63%
890,000
– –
XENT
57
DELISTED
Intersect ENT, Inc
XENT
$14.8M 0.59%
872,500
+82,500
+10% +$1.5M
ARDX icon
58
Ardelyx
ARDX
$997M
$14.4M 0.57%
3,055,261
+1,055,261
+53% +$3.67M
BHVN
59
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$14.3M 0.57%
343,500
– –
ACHN
60
DELISTED
Achillion Pharmaceuticals
ACHN
$13.8M 0.55%
3,825,000
+875,000
+30% +$3.37M
SAGE
61
DELISTED
Sage Therapeutics
SAGE
$13M 0.52%
92,500
– –
NVCR icon
62
NovoCure
NVCR
$1.91B
$12.9M 0.51%
172,500
-22,500
-12% -$1.8M
GBT
63
DELISTED
Global Blood Therapeutics, Inc.
GBT
$12.9M 0.51%
265,000
– –
ASMB icon
64
Assembly Biosciences
ASMB
$529M
$12.8M 0.51%
108,333
+61,666
+132% +$9.33M
GH icon
65
Guardant Health
GH
$22.6B
$12.1M 0.48%
190,000
– –
IMMU
66
DELISTED
Immunomedics Inc
IMMU
$11.9M 0.47%
895,000
– –
BOLD
67
DELISTED
Audentes Therapeutics, Inc
BOLD
$11.5M 0.46%
410,000
– –
AGIO icon
68
Agios Pharmaceuticals
AGIO
$1.93B
$11.4M 0.46%
352,500
+182,000
+107% +$7.53M
OBSV
69
DELISTED
ObsEva SA Ordinary Shares
OBSV
$11.3M 0.45%
1,360,000
+240,000
+21% +$2.29M
KYNB
70
Kyntra Bio
KYNB
$29.4M
$11.3M 0.45%
12,240
– –
ODT
71
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$11.2M 0.45%
430,000
– –
TVTX icon
72
Travere Therapeutics
TVTX
$5.78B
$11M 0.44%
950,000
– –
GWPH
73
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$10.9M 0.44%
95,000
-510,000
-84% -$77.4M
TBPH icon
74
Theravance Biopharma
TBPH
$877M
$10.7M 0.43%
550,000
– –
ABT icon
75
Abbott
ABT
$187B
$10.3M 0.41%
+122,500
New +$10.4M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Rock Springs Capital Management held 145 positions worth $2.51B, down 9.2% from $2.76B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management's Q3 2019 filing shows 11 new, 46 increased, 10 reduced and 7 closed positions. Its largest new stake was Amgen: 126,000 shares worth $24.4M. The largest sale was GW Pharmaceuticals Plc American Depositary Shares, an estimated $77.4M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier, followed by Consumer Staples.

  • Rock Springs Capital Management's largest Q3 2019 buy was Amgen: 126,000 shares worth $24.4M.
  • Rock Springs Capital Management added most to AbbVie in Q3 2019, an estimated $25.7M increase.
  • Rock Springs Capital Management's biggest Q3 2019 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $77.4M.
  • Rock Springs Capital Management fully exited Bristol-Myers Squibb in Q3 2019, selling an estimated $47.6M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.51B portfolio in Q3 2019.
  • Rock Springs Capital Management opened 11 new positions and closed 7 in Q3 2019.
  • Rock Springs Capital Management's portfolio value fell 9.2% quarter-over-quarter to $2.51B.

Based on Rock Springs Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.